News & Events

Besides our engagement in Melanoma Research, we will also focus on Research in Non Melanoma Skin Cancer, starting with BCCs and SCCs, in the near future. We are in the final stages of technical realiz...

We are pleased to announce that Sheba Tel-HaShomer Medical Center, specifically the Ella Lemelbaum Institute for Immun-Oncology and Melanoma (which is part of the Sheba Cancer Research Centre) has joi...

After two virtual meetings in the past two years, which were due to the COVID-19 pandemic, the EUMelaReg Annual Meeting was finally held face to face again this year. Although not everyone could be th...

Our first, already mentioned in the last newsletter, EUMelaReg abstract submission of the EMR-SEQ project (registry-based outcome analysis of 1,000 patients with BRAF V600 mutant metastatic melanoma i...

The collaboration between EMR and EADO is beginning to bear fruit: the survey on access to standard systemic treatment for metastatic melanoma launched within EADO and EMR was presented by Lidija Kand...

On Saturday, 23rd April, an EUMelaReg symposium chaired by Celeste Lebbé and Lidija Kandolf Sekulovic will be held. There will be three main topics: 1. "European Melanoma and NMSC registry“ presenting...

We are very pleased to announce that as of today there are more than 8,100 documented, quality checked, cases in the European Melanoma Registry. This is an increase of about 15 % since the beginning o...

For our EMRseq project an ASCO Abstract has been successfully submitted. EMRseq is a Registry based outcome analysis on 1,000 patients with BRAF V600 mutated metastatic melanoma in Europe treated with...

Besides our engagement in Melanoma Research, we will also focus on Research in Non Melanoma Skin Cancer, starting with BCCs and SCCs, in the near future. We are in the final stages of technical realiz...

We are pleased to announce that Sheba Tel-HaShomer Medical Center, specifically the Ella Lemelbaum Institute for Immun-Oncology and Melanoma (which is part of the Sheba Cancer Research Centre) has joi...

After two virtual meetings in the past two years, which were due to the COVID-19 pandemic, the EUMelaReg Annual Meeting was finally held face to face again this year. Although not everyone could be th...

Our first, already mentioned in the last newsletter, EUMelaReg abstract submission of the EMR-SEQ project (registry-based outcome analysis of 1,000 patients with BRAF V600 mutant metastatic melanoma i...

The collaboration between EMR and EADO is beginning to bear fruit: the survey on access to standard systemic treatment for metastatic melanoma launched within EADO and EMR was presented by Lidija Kand...

On Saturday, 23rd April, an EUMelaReg symposium chaired by Celeste Lebbé and Lidija Kandolf Sekulovic will be held. There will be three main topics: 1. "European Melanoma and NMSC registry“ presenting...

We are very pleased to announce that as of today there are more than 8,100 documented, quality checked, cases in the European Melanoma Registry. This is an increase of about 15 % since the beginning o...

For our EMRseq project an ASCO Abstract has been successfully submitted. EMRseq is a Registry based outcome analysis on 1,000 patients with BRAF V600 mutated metastatic melanoma in Europe treated with...